JP2006503888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503888A5 JP2006503888A5 JP2004546022A JP2004546022A JP2006503888A5 JP 2006503888 A5 JP2006503888 A5 JP 2006503888A5 JP 2004546022 A JP2004546022 A JP 2004546022A JP 2004546022 A JP2004546022 A JP 2004546022A JP 2006503888 A5 JP2006503888 A5 JP 2006503888A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- phenyl
- hydroxyethyl
- amino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- CMKZQSHWRVZOOY-PMERELPUSA-N 4-[(1r)-2-[6-[4-(3-cyclopentylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCCCC=2C=C(C=CC=2)S(=O)(=O)C2CCCC2)=C1 CMKZQSHWRVZOOY-PMERELPUSA-N 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- IPMLTYNMMWXXGZ-RFPXNCDYSA-N 4-[(1r)-2-[6-[4-(3-cyclopentylsulfinylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCCCC=2C=C(C=CC=2)S(=O)C2CCCC2)=C1 IPMLTYNMMWXXGZ-RFPXNCDYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- -1 aryl sulfonic acid Chemical compound 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000000543 intermediate Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- AHBQEXAYASMAHF-HKBQPEDESA-N 4-[(1r)-2-[6-[4-(3-cyclohexylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCCCC=2C=C(C=CC=2)S(=O)(=O)C2CCCCC2)=C1 AHBQEXAYASMAHF-HKBQPEDESA-N 0.000 claims 1
- NHCKCBLLRKMQRA-PMERELPUSA-N 4-[(1r)-2-[6-[4-(3-cyclopent-3-en-1-ylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCCCC=2C=C(C=CC=2)S(=O)(=O)C2CC=CC2)=C1 NHCKCBLLRKMQRA-PMERELPUSA-N 0.000 claims 1
- QZWUZHTUCRGGJA-HKBQPEDESA-N 4-[(1r)-2-[6-[4-(3-cyclopentylsulfonyl-5-methylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1([C@@H](O)CNCCCCCCOCCCCC=2C=C(C=C(C=2)S(=O)(=O)C2CCCC2)C)=CC=C(O)C(CO)=C1 QZWUZHTUCRGGJA-HKBQPEDESA-N 0.000 claims 1
- RDCHCGRUXILZCM-LJAQVGFWSA-N 4-[(1r)-2-[6-[4-(3-cyclopentylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-fluorophenol Chemical compound C([C@H](O)C=1C=C(F)C(O)=CC=1)NCCCCCCOCCCCC(C=1)=CC=CC=1S(=O)(=O)C1CCCC1 RDCHCGRUXILZCM-LJAQVGFWSA-N 0.000 claims 1
- XGHCBYFGZZQETE-PMERELPUSA-N 4-[(1r)-2-[6-[4-(4-cyclopentylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCCCC=2C=CC(=CC=2)S(=O)(=O)C2CCCC2)=C1 XGHCBYFGZZQETE-PMERELPUSA-N 0.000 claims 1
- DXDPRGIAAPVRTR-HKBQPEDESA-N 4-[(1r)-2-[6-[5-(3-cyclopentylsulfonylphenyl)pentoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCCCCC=2C=C(C=CC=2)S(=O)(=O)C2CCCC2)=C1 DXDPRGIAAPVRTR-HKBQPEDESA-N 0.000 claims 1
- SRDARHPKSYCJOG-PMERELPUSA-N 4-[(1r)-2-[7-[3-(3-cyclopentylsulfonylphenyl)propoxy]heptylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCCOCCCC=2C=C(C=CC=2)S(=O)(=O)C2CCCC2)=C1 SRDARHPKSYCJOG-PMERELPUSA-N 0.000 claims 1
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 claims 1
- RJWBTWIBUIGANW-UHFFFAOYSA-M 4-chlorobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-M 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- VYRGLNWZLZWKFP-PMERELPUSA-N 5-[(1r)-2-[6-[4-(3-cyclopentylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-8-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound C([C@H](O)C=1C=2CCC(=O)NC=2C(O)=CC=1)NCCCCCCOCCCCC(C=1)=CC=CC=1S(=O)(=O)C1CCCC1 VYRGLNWZLZWKFP-PMERELPUSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- CDAKJSRRZUGPEG-UHFFFAOYSA-N 6-[2-[6-[4-(3-cyclopentylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol Chemical compound C1=C(O)C(CO)=NC(C(O)CNCCCCCCOCCCCC=2C=C(C=CC=2)S(=O)(=O)C2CCCC2)=C1 CDAKJSRRZUGPEG-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- OAQRLDKPZZCJKS-BHVANESWSA-N [4-[(1R)-2-[6-[4-(3-cyclopentylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenyl] 3-methylbenzenesulfonate Chemical compound Cc1cccc(c1)S(=O)(=O)Oc1ccc(cc1CO)[C@@H](O)CNCCCCCCOCCCCc1cccc(c1)S(=O)(=O)C1CCCC1 OAQRLDKPZZCJKS-BHVANESWSA-N 0.000 claims 1
- ZZGJVOZYVRSHNK-RWYGWLOXSA-N [4-[(1R)-2-[6-[4-(3-cyclopentylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenyl] 4-phenylbenzenesulfonate Chemical compound C1(=CC=C(C=C1)S(=O)(=O)OC1=C(C=C(C=C1)[C@H](CNCCCCCCOCCCCC1=CC(=CC=C1)S(=O)(=O)C1CCCC1)O)CO)C1=CC=CC=C1 ZZGJVOZYVRSHNK-RWYGWLOXSA-N 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- UGNBYGPBCLYWCL-PMERELPUSA-N n-[5-[(1r)-2-[6-[4-(3-cyclopentylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-hydroxyphenyl]formamide Chemical compound C([C@H](O)C=1C=C(NC=O)C(O)=CC=1)NCCCCCCOCCCCC(C=1)=CC=CC=1S(=O)(=O)C1CCCC1 UGNBYGPBCLYWCL-PMERELPUSA-N 0.000 claims 1
- GDRIEPJFIXGEBM-PMERELPUSA-N n-[5-[(1r)-2-[6-[4-(3-cyclopentylsulfonylphenyl)butoxy]hexylamino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide Chemical compound C1=C(O)C(NS(=O)(=O)C)=CC([C@@H](O)CNCCCCCCOCCCCC=2C=C(C=CC=2)S(=O)(=O)C2CCCC2)=C1 GDRIEPJFIXGEBM-PMERELPUSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000003871 sulfonates Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0225022A GB0225022D0 (en) | 2002-10-28 | 2002-10-28 | Chemical compounds |
| GB0225028A GB0225028D0 (en) | 2002-10-28 | 2002-10-28 | Chemical compounds |
| PCT/EP2003/012035 WO2004037773A1 (en) | 2002-10-28 | 2003-10-24 | Phenethanolamine derivative for the treatment of respiratory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503888A JP2006503888A (ja) | 2006-02-02 |
| JP2006503888A5 true JP2006503888A5 (enExample) | 2006-11-02 |
Family
ID=32178883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004546022A Pending JP2006503888A (ja) | 2002-10-28 | 2003-10-24 | 呼吸器疾患を治療するためのフェネタノールアミン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7442839B2 (enExample) |
| EP (1) | EP1556342B1 (enExample) |
| JP (1) | JP2006503888A (enExample) |
| KR (1) | KR20050057681A (enExample) |
| AR (1) | AR041724A1 (enExample) |
| AT (1) | ATE390407T1 (enExample) |
| AU (1) | AU2003286143A1 (enExample) |
| BR (1) | BR0315720A (enExample) |
| CA (1) | CA2503588A1 (enExample) |
| DE (1) | DE60320007T2 (enExample) |
| DK (1) | DK1556342T3 (enExample) |
| ES (1) | ES2302956T3 (enExample) |
| IS (1) | IS7814A (enExample) |
| MA (1) | MA27697A1 (enExample) |
| MX (1) | MXPA05004527A (enExample) |
| NO (1) | NO20051962L (enExample) |
| NZ (1) | NZ539676A (enExample) |
| PL (1) | PL377122A1 (enExample) |
| PT (1) | PT1556342E (enExample) |
| RU (1) | RU2332400C2 (enExample) |
| SI (1) | SI1556342T1 (enExample) |
| TW (1) | TWI285195B (enExample) |
| WO (1) | WO2004037773A1 (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1487417A4 (en) | 2001-09-17 | 2010-03-17 | Glaxo Group Ltd | DRY POWDER DRUG FORMULATIONS |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| GB0324886D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
| PE20061351A1 (es) | 2005-03-25 | 2007-01-14 | Glaxo Group Ltd | COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38 |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| EP2281813A1 (en) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
| JP5006330B2 (ja) | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Ｉｌ１３に対するヒト抗体および治療的使用 |
| PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| TW200811111A (en) | 2006-04-20 | 2008-03-01 | Glaxo Group Ltd | Novel compounds |
| HRP20120494T1 (hr) | 2006-04-21 | 2012-08-31 | Novartis Ag | Derivati purina za uporabu kao agonista adenozin a2a receptora |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| AR061571A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un |
| WO2008015416A1 (en) | 2006-08-01 | 2008-02-07 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| CA2673803A1 (en) | 2007-01-10 | 2008-07-17 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| ES2361595T3 (es) | 2007-05-07 | 2011-06-20 | Novartis Ag | Compuestos orgánicos. |
| KR101578235B1 (ko) | 2007-12-10 | 2015-12-16 | 노파르티스 아게 | 유기 화합물 |
| WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
| SG190667A1 (en) | 2008-05-23 | 2013-06-28 | Panmira Pharmaceuticals Llc | 5-lipoxygenase-activating protein inhibitor |
| ES2566339T3 (es) | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas |
| AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| PL2379507T3 (pl) | 2008-12-30 | 2014-03-31 | Pulmagen Therapeutics Inflammation Ltd | Związki sulfonamidu do leczenia zaburzeń układu oddechowego |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| EP2408916A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| KR20110137799A (ko) | 2009-03-19 | 2011-12-23 | 머크 샤프 앤드 돔 코포레이션 | 짧은 간섭 핵산 (ｓｉＮＡ) 서열 목록을 사용한 ＢＴＢ 및 ＣＮＣ 상동체 1, 염기성 류신 지퍼 전사 인자 1 (ＢＡＣＨ1) 유전자 발현의 ＲＮＡ 간섭 매개 억제 |
| EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| AU2010229847A1 (en) | 2009-03-27 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA) |
| EP2411019A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| TW201103892A (en) | 2009-04-24 | 2011-02-01 | Glaxo Group Ltd | Compounds |
| ES2644724T3 (es) | 2009-04-30 | 2017-11-30 | Glaxo Group Limited | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| EP2507226A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Novel compounds |
| JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| US20120238571A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Indazole derivatives as pi 3-kinase |
| EP2512438B1 (en) | 2009-12-16 | 2017-01-25 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| HUE026059T2 (en) | 2010-09-08 | 2016-05-30 | Glaxosmithkline Ip Dev Ltd | N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
| EP2630127A1 (en) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| EP2755967B1 (en) | 2011-09-16 | 2015-10-21 | Novartis AG | Heterocyclic compounds for the treatment of cystic fibrosis |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| AU2014336250A1 (en) | 2013-10-17 | 2016-04-14 | Glaxosmithkline Intellectual Property Development Limited | PI3K inhibitor for treatment of respiratory disease |
| US20160263109A1 (en) | 2013-10-17 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | P13k inhibitor for treatment of respiratory disease |
| JP6404944B2 (ja) | 2014-04-24 | 2018-10-17 | ノバルティス アーゲー | ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体 |
| EP3134397A1 (en) | 2014-04-24 | 2017-03-01 | Novartis AG | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| EA201692140A1 (ru) | 2014-04-24 | 2017-04-28 | Новартис Аг | Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы |
| JP2017515840A (ja) | 2014-05-12 | 2017-06-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | 感染症を治療するためのダニリキシンを含む医薬組成物 |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| EP3497100A1 (en) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| EP3980121A1 (en) | 2019-06-10 | 2022-04-13 | Novartis AG | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
| CN114341132A (zh) | 2019-08-28 | 2022-04-12 | 诺华股份有限公司 | 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途 |
| WO2023097697A1 (zh) * | 2021-12-03 | 2023-06-08 | 广东莱佛士制药技术有限公司 | 一种合成(1r)-1-(2,2-二甲基-4h-1,3-苯并二噁英-6-基)噁唑啉-2-酮的方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2918408A (en) | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodic compositions specific for treating spasm of the colon |
| GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
| IT1203660B (it) | 1982-10-08 | 1989-02-15 | Glaxo Group Ltd | Dispositivi per somministrare farmaci a pazienti e confezione di blister per essi |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| AU581887B2 (en) | 1984-04-17 | 1989-03-09 | Glaxo Group Limited | Ethanolamine compounds |
| DK173785A (da) | 1984-04-17 | 1985-10-18 | Glaxo Group Ltd | Phenylethanolaminderivater |
| KR910000932B1 (ko) | 1984-04-18 | 1991-02-19 | 가부시기가이샤 다이킨세이사꾸쇼 | 차량용 트랜스퍼장치 |
| SE8503466L (sv) | 1984-07-13 | 1986-01-14 | Glaxo Group Ltd | Aminofenolforeningar |
| GB8426191D0 (en) | 1984-10-17 | 1984-11-21 | Glaxo Holdings Ltd | Chemical compounds |
| GB2178965B (en) | 1985-07-30 | 1988-08-03 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| EP0220054A3 (en) | 1985-10-16 | 1987-12-02 | Glaxo Group Limited | Ethanolamine derivatives |
| GB2230523A (en) | 1989-04-14 | 1990-10-24 | Glaxo Group Ltd | 1-(3-Bromoisoxazol-5-yl)-2-aminoethanol derivatives |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SK279958B6 (sk) | 1992-04-02 | 1999-06-11 | Smithkline Beecham Corporation | Zlúčeniny s protialergickým a protizápalovým účink |
| US5998428A (en) | 1995-05-31 | 1999-12-07 | Smithkline Beecham Corporation | Compounds and methods for treating PDE IV-related diseases |
| EP0947498B1 (en) | 1996-12-02 | 2004-09-15 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same |
| AU5723098A (en) | 1996-12-30 | 1998-07-31 | American Home Products Corporation | Substituted benzo{1,4}dioxanes as antiobesity agents |
| GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| SI1070056T1 (en) | 1998-03-14 | 2004-12-31 | Altana Pharma Ag | Phthalazinone pde iii/iv inhibitors |
| AR035987A1 (es) | 1999-03-01 | 2004-08-04 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio |
| HU229439B1 (hu) | 1999-08-21 | 2013-12-30 | Takeda Gmbh | Roflumilast és salmeterol szinergetikus kombinációja |
| GB0014546D0 (en) | 2000-06-14 | 2000-08-09 | Glaxo Group Ltd | A novel process |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| BRPI0212455B8 (pt) | 2001-09-14 | 2021-05-25 | Glaxo Group Ltd | composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo |
| WO2004037807A2 (en) | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
-
2003
- 2003-10-24 NZ NZ539676A patent/NZ539676A/en unknown
- 2003-10-24 AU AU2003286143A patent/AU2003286143A1/en not_active Abandoned
- 2003-10-24 PL PL377122A patent/PL377122A1/pl not_active Application Discontinuation
- 2003-10-24 AT AT03776873T patent/ATE390407T1/de not_active IP Right Cessation
- 2003-10-24 WO PCT/EP2003/012035 patent/WO2004037773A1/en not_active Ceased
- 2003-10-24 SI SI200331215T patent/SI1556342T1/sl unknown
- 2003-10-24 DK DK03776873T patent/DK1556342T3/da active
- 2003-10-24 PT PT03776873T patent/PT1556342E/pt unknown
- 2003-10-24 EP EP03776873A patent/EP1556342B1/en not_active Expired - Lifetime
- 2003-10-24 US US10/532,869 patent/US7442839B2/en not_active Expired - Fee Related
- 2003-10-24 JP JP2004546022A patent/JP2006503888A/ja active Pending
- 2003-10-24 DE DE60320007T patent/DE60320007T2/de not_active Expired - Fee Related
- 2003-10-24 BR BR0315720-2A patent/BR0315720A/pt not_active IP Right Cessation
- 2003-10-24 CA CA002503588A patent/CA2503588A1/en not_active Abandoned
- 2003-10-24 ES ES03776873T patent/ES2302956T3/es not_active Expired - Lifetime
- 2003-10-24 KR KR1020057007275A patent/KR20050057681A/ko not_active Ceased
- 2003-10-24 MX MXPA05004527A patent/MXPA05004527A/es active IP Right Grant
- 2003-10-24 AR ARP030103896A patent/AR041724A1/es unknown
- 2003-10-24 RU RU2005111975/04A patent/RU2332400C2/ru not_active IP Right Cessation
- 2003-10-27 TW TW092129753A patent/TWI285195B/zh not_active IP Right Cessation
-
2005
- 2005-04-20 IS IS7814A patent/IS7814A/is unknown
- 2005-04-21 NO NO20051962A patent/NO20051962L/no not_active Application Discontinuation
- 2005-05-11 MA MA28274A patent/MA27697A1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503888A5 (enExample) | ||
| RU2332400C2 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| US7932273B2 (en) | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament | |
| WO2001013917A1 (en) | Npy antagonists: spiroisoquinolinone derivatives | |
| LU84011A1 (fr) | 2-phenoxyalkyl-1,2,4-triazol-3-ones antidepressives | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2007509852A5 (enExample) | ||
| JP2007514691A5 (enExample) | ||
| CZ39396A3 (en) | The use of substituted aryloxyalkyldiamines, the compounds per se, process of their preparation, pharmaceutical compositions based thereon and process of their preparation | |
| US20120238615A1 (en) | Alpha adrenergic receptor modulators | |
| JP2011529090A (ja) | アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用 | |
| JP2004269469A (ja) | ピリミジン誘導体又はその塩 | |
| RU2272036C2 (ru) | Способ получения мезилатов производных пиперазина | |
| JP2010517969A (ja) | クロメンｓ１ｐ１受容体アンタゴニスト | |
| JPH0473432B2 (enExample) | ||
| AU2021299200A1 (en) | Processes for making SERD tricyclic compounds having a substituted phenyl or pyridinyl moiety | |
| JP2005247691A (ja) | Ｓ１ｐ３受容体拮抗薬 | |
| US6673939B2 (en) | Process for the preparation of 1,2,4-triazolin-5-one derivatives | |
| CN87103528A (zh) | 1，3-二取代的咪唑盐类 | |
| US7163953B2 (en) | Benzylether derivatives | |
| US20060173192A1 (en) | Aminoalkylphenyl indolone derivatives | |
| JP2024541320A (ja) | 特定のメソイオン性殺虫剤の調製プロセス | |
| EP0699675A2 (en) | 3-(4-(1-Substituted-4-piperazinyl)butyl)-4-thiazolidinone and related compounds | |
| CN1533278A (zh) | 萘并噻嗪正变构的ampa受体调节物(paarm) | |
| CN1138333A (zh) | 新的哒嗪并[4′,5′∶3，4]吡咯并-[2，1-a]异喹啉及其在制备药物制剂中的应用 |